An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Sylvant

Chemical Namesiltuximab
Dosage FormInjection (intravenous; 100mg, 400mg)
Drug ClassReceptor antagonists
SystemBlood
CompanyJanssen Biotech
Approval Year2014

Indication

  • For the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sylvant (siltuximab) Prescribing Information 2014Janssen Biotech, Inc. Horsham, PA 19044
Document TitleYearSource
Clinical guidance report: Sylvant for multicentric castleman's disease.2015CADTH
Economic guidance report: Sylvant for multicentric castleman's disease. 2015CADTH